At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 104 enrolled
Drug / intervention
omega 3drug
Likely dose
omega 3 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3 Study of Poly Unsaturated Fatty Acids of Omega 3 as an Anti Platelet Agent on Biomarkers of Cardiac Necrosis Including CKMB and Troponin I and Inflammation Marker CRP
Shahid Beheshti University of Medical Sciences·interventional·Posted Jan 31, 2012·Updated Dec 10, 2012
In Brief
A Phase 3 clinical trial evaluating omega 3 for Coronary Arteriosclerosis. Completed, enrolled 104 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the effect of omega 3 on biomarkers of cardiac necrosis(CKMB and troponin I) and inflammation marker CRP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Arteriosclerosis
CountriesIran
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedJan 2012
Primary CompletionMay 2012
TodayJul 2026
First PostedJan 31, 2012
Enrollment StartJan 1, 2012
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 14.4 years ago
Interventions
omega 3drug
3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI